<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629159</url>
  </required_header>
  <id_info>
    <org_study_id>M14-465</org_study_id>
    <secondary_id>2015-003333-95</secondary_id>
    <nct_id>NCT02629159</nct_id>
  </id_info>
  <brief_title>A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate</brief_title>
  <acronym>SELECT-COMPARE</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess efficacy, including inhibition of radiographic
      progression, and safety with upadacitinib versus placebo and versus an active comparator,
      adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who
      are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a 48-week double-blind treatment period (Period 1) and a long-term
      extension period (Period 2).

      Period 1 is a 48-week randomized, double-blind, parallel-group, placebo-controlled and active
      comparator-controlled period designed to compare the safety and efficacy of upadacitinib
      versus placebo, and versus adalimumab. Participants will be randomized in a 2:2:1 ratio to
      one of three treatment groups:

        -  Placebo (up to Week 26)

        -  Upadacitinib 15 mg once daily (QD)

        -  Adalimumab 40 mg every other week (eow)

      Participants randomized to placebo who do not achieve a ≥ 20% improvement in tender joint
      count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline will be
      switched to blinded upadacitinib treatment. At Week 26, all participants still receiving
      placebo will be switched to blinded upadacitinib treatment regardless of clinical response.

      Participants randomized to adalimumab who do not achieve a ≥ 20% improvement in TJC and SJC
      at Weeks 14, 18, or 22 compared to Baseline will be switched to blinded upadacitinib.
      Participants still receiving adalimumab at Week 26 who do not achieve low disease activity
      (LDA) according to Clinical Disease Activity Index (CDAI; LDA is defined as CDAI ≤ 10) will
      be switched to blinded upadacitinib treatment to Week 48.

      Participants randomized to upadacitinib who do not achieve a ≥ 20% improvement in TJC and SJC
      at Weeks 14, 18, or 22 compared to Baseline will be switched to blinded adalimumab;
      participants still receiving upadacitinib at Week 26 who do not achieve LDA (CDAI ≤ 10) will
      be switched to blinded adalimumab treatment to Week 48.

      Participants who complete the Week 48 visit (end of Period 1) will enter the long-term
      extension phase of the study (Period 2), for up to 5 years. Participants will continue study
      treatment as assigned at the end of Period 1. Starting at the Week 48 and thereafter, at
      least 20% improvement in both TJC and SJC compared to Baseline is required to remain on study
      drug. Anyone who does not fulfill this criterion at 2 consecutive visits (starting at Week
      48) will be discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Anticipated">May 20, 2022</completion_date>
  <primary_completion_date type="Actual">October 27, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission, based on a Disease Activity Score 28 (DAS28)-CRP score of &lt; 2.6 at Week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than 2.6 indicates clinical remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (CRP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The mTSS measures the level of joint damage from radiographs of the hands and feet, assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score.
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
JSN was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).
The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst). A negative change from Baseline in mTSS indicates improvement in joint damage whereas a change from Baseline greater than 0 indicates progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duration of Morning Stiffness at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100. A score of 0 indicates &quot;no pain&quot; and a score of 100 indicates &quot;worst possible pain.&quot; A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Radiographic Progression at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>No radiographic progression is defined as a change from Baseline in mTSS ≤ 0. The mTSS measures the level of joint damage from radiographs of the hands and feet, which were assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score and ranges from 0 (normal) to 448 (worst).
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
Joint space narrowing (JSN) was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1629</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo followed by ABT-494</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).
Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.
Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.
Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Adalimumab</intervention_name>
    <description>Administered by subcutaneous injection once every other week</description>
    <arm_group_label>Placebo followed by ABT-494</arm_group_label>
    <arm_group_label>Upadacitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Administered by subcutaneous injection once every other week</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Upadacitinib</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Upadacitinib</intervention_name>
    <description>Tablets taken orally once a day</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Tablets taken orally once a day</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494</arm_group_label>
    <arm_group_label>Upadacitinib</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female, at least 18 years old.

          -  Diagnosis of RA for greater than or equal to 3 months.

          -  Subjects must have been on oral or parenteral methotrexate (MTX) therapy greater than
             or equal to 3 months and on a stable prescription of greater than or equal to 15 to 25
             mg/week (or greater than or equal to 10 mg/week in subjects intolerant of MTX at doses
             greater than or equal to 12.5 mg/week) for at least 4 weeks prior to the first dose of
             study drug. In addition all subjects should take a dietary supplement of folic acid or
             folinic acid throughout the study participation.

          -  Meets the following minimum disease activity criteria: greater than or equal to 6
             swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  At least one of the following at Screening: greater than or equal to 3 bone erosions
             on x-ray OR greater than or equal to 1 bone erosion and a positive rheumatoid factor
             OR greater than or equal to 1 bone erosion and a positive anti-cyclic citrullinated
             peptide autoantibodies.

          -  Subjects with prior exposure to only one biological disease-modifying anti-rheumatic
             drugs (bDMARD) (except adalimumab) may be enrolled (up to 20% of total study
             population) if they have documented evidence of intolerance to the bDMARD or limited
             exposure (less than 3 months), but required washout periods need to be satisfied.

          -  Except for MTX, subject must have discontinued all conventional synthetic
             disease-modifying anti-rheumatic drugs (csDMARDs).

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Subjects who have been exposed to adalimumab or who are considered inadequate
             responders to bDMARD therapy as determined by the Investigator.

          -  History of inflammatory joint disease other than RA. History of secondary Sjogren's
             Syndrome is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC /ID# 143136</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Assoc /ID# 143130</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SunValley Arthritis Center, Lt /ID# 143123</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies, LLC /ID# 144881</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 143080</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 143121</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheuma Research /ID# 143131</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center, Inc. /ID# 144877</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053-4061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheum Research /ID# 156093</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - North Campus /ID# 143114</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719-1478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteoporosis Medical Center /ID# 153935</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T. Joseph Raoof, MD, Inc. /ID# 144884</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Ctr of San Diego /ID# 153747</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.V. Mehta MD, Med Corporation /ID# 143116</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Rheum Med Clin /ID# 146083</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kotha and Kotha /ID# 161046</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates- La Mesa /ID# 143115</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerius Med Grp &amp; Res Ctr /ID# 143120</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720-5402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc /ID# 163504</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances /ID# 143097</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Rheumatology /ID# 155672</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin K. Dore MD, Inc /ID# 143090</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research /ID# 148362</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Assoc &amp; Osteo Ctr /ID# 143122</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheum Clin N. CO /ID# 156094</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARDS Research, Inc. /ID# 154190</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZASA Clinical Research /ID# 143134</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Res of West FL, Inc. /ID# 143112</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Research /ID# 143132</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Org, LLC /ID# 143092</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016-1501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Research, LLC /ID# 145630</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FL Med Ctr and Research, Inc. /ID# 143081</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr Arthritis &amp; Rheumatic Dise /ID# 143135</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clin Res of Orlando /ID# 154617</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761-4547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheum Assoc of Central FL /ID# 145632</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants /ID# 145635</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMD Research LLC /ID# 163292</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research of Florida /ID# 143125</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684-2672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, Inc. /ID# 145647</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony Comprehsve Res Ins /ID# 143095</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West FL /ID# 148358</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW FL Clin Res Ctr, Tampa, FL /ID# 143117</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group, Inc. /ID# 143085</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614-7101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources /ID# 143106</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology /ID# 155668</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of North GA /ID# 155258</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology Grp /ID# 147170</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research /ID# 153090</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials /ID# 148357</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Treatment Center /ID# 155260</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology &amp; /ID# 151356</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Gr /ID# 143082</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology, PC /ID# 143118</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shores Rheumatology, PC /ID# 162977</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital /ID# 156750</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Med Clinics /ID# 145636</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Res. Collaboration /ID# 143087</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Inc. /ID# 156394</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Coast Research /ID# 148355</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Rheumatology, PA /ID# 143111</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Rheumatic Back Disorder /ID# 143102</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc /ID# 143083</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteo Assoc /ID# 143127</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lawrence Health System /ID# 161619</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint &amp; Muscle Research Instit /ID# 143119</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC /ID# 143101</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EmergeOrtho, P.A. /ID# 143100</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Fear Arthritis Care /ID# 148361</name>
      <address>
        <city>Leland</city>
        <state>North Carolina</state>
        <zip>28451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Health Care /ID# 148359</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanahan Rheuma &amp; Immuno /ID# 145643</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC /ID# 154619</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Assoc of NW Ohio /ID# 143094</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultant /ID# 143129</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr Clinical Res /ID# 143110</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Ctr Reading /ID# 143133</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Arthritis Center /ID# 153730</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research /ID# 145637</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 143091</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486-7887</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates, PLLC /ID# 155490</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Consultants, PLLC /ID# 153731</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ramesh Gupta /ID# 143099</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic /ID# 143084</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Group Integrated He /ID# 148356</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care and Diagnostic /ID# 150677</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research /ID# 145631</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Hosp at Renaissance /ID# 154616</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedResearch Inc. /ID# 154618</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management /ID# 145644</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research /ID# 145645</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic of Houston /ID# 150921</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clin Res /ID# 144879</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc. /ID# 145640</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098-5294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Consultants, P.A. /ID# 144880</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Assoc /ID# 147364</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P&amp;I Clinical Research /ID# 161625</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904-3132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Rheumatology Res. LLC /ID# 143126</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc. /ID# 162578</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459-4750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc. /ID# 163183</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459-4750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc. /ID# 163184</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459-4750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute /ID# 159539</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management /ID# 143089</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteo Ctr of S. TX /ID# 143103</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research /ID# 151357</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of N. VA, P.C /ID# 143109</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr for Arth and Rheum Disease /ID# 143113</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC /ID# 143088</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic, INC. PS /ID# 143107</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia Research Inst /ID# 153088</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Immunotherapy Center /ID# 145646</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aprillus Asistencia e Investig /ID# 148406</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1046</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mautalen Salud e Investigacion /ID# 142843</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1128</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Sanatorio Guemes /ID# 148405</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1180</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Reumatologic Pampa /ID# 144853</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cemic /Id# 148404</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1431</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Org Medica de Investigacion /ID# 144855</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Rheumatologic Strusberg /ID# 145601</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultora Integral de Salud S /ID# 144856</name>
      <address>
        <city>Cordoba</city>
        <zip>5900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto CAICI /ID# 144854</name>
      <address>
        <city>Rosario, Santa FE</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cordis S.A. /Id# 152622</name>
      <address>
        <city>Salta</city>
        <zip>4400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iari /Id# 151293</name>
      <address>
        <city>San Fernando</city>
        <zip>1646</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologi /ID# 142845</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado/Reuma /ID# 142842</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Enfermedades /ID# 153542</name>
      <address>
        <city>Santa Fe</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital /ID# 144857</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research /ID# 142848</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz /ID# 142851</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First City Clinical Hospital /ID# 158011</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 142858</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhumaconsult SPRL /ID# 142860</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege /ID# 148401</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent /ID# 142859</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare /ID# 152953</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska /ID# 142862</name>
      <address>
        <city>Banja Luka</city>
        <state>Republika Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska /ID# 142863</name>
      <address>
        <city>Banja Luka</city>
        <state>Republika Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo /ID# 142865</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIP - Centro Internacional de Pesquisa /ID# 142872</name>
      <address>
        <city>Goiânia</city>
        <state>Goias</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hc Ufmg /Id# 142868</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 142871</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre /ID# 142870</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Sevicos Medicos S/S /ID# 142869</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 142867</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Brasil /ID# 150918</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Trimontsium /ID# 142874</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Pulmed OOD /ID# 142877</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Kaspela /ID# 142873</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center /ID# 142875</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski /ID# 142876</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 161434</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A IM3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciads /Id# 142880</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare's Mercy Hospital /ID# 142879</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Prof. Corp /ID# 154205</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA Ctr for Clin Trials CCCT /ID# 157379</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Maladies Osseuses /ID# 142878</name>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr de Inv Clinica del Sur /ID# 142888</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781156</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reg. Clinical Hosptial Concepcion /ID# 151271</name>
      <address>
        <city>Concepcion</city>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corp de Beneficencia Osorno /ID# 147941</name>
      <address>
        <city>Osorno</city>
        <zip>1710216</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Someal /Id# 144704</name>
      <address>
        <city>Providencia-santiago</city>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Research LTDA. /ID# 142893</name>
      <address>
        <city>Puerto Varas</city>
        <zip>5550170</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Research Stgo. /ID# 157933</name>
      <address>
        <city>Santiago</city>
        <zip>7500588</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soc. de Prestaciones medicas y Paramedicas Goecke /ID# 142890</name>
      <address>
        <city>Santiago</city>
        <zip>7510047</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica DermaCross /ID# 142892</name>
      <address>
        <city>Santiago</city>
        <zip>7640881</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Medicas SSMSO /ID# 151686</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Inter Estud Clin CIEC /ID# 144777</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico de Reumatologia /ID# 148402</name>
      <address>
        <city>Temuco</city>
        <zip>4790928</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cinvec /Id# 144705</name>
      <address>
        <city>Vina Del Mar</city>
        <zip>2520997</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 142898</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr Int de Reum del Caribe SAS /ID# 142894</name>
      <address>
        <city>Barranquilla</city>
        <zip>80002</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fund Inst de Reum F. Chalem /ID# 149847</name>
      <address>
        <city>Bogota DC</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A - CAYRE /ID# 142896</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S. /ID# 144860</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologi /ID# 142897</name>
      <address>
        <city>Medellín</city>
        <zip>50021</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Rijeka /ID# 160232</name>
      <address>
        <city>Rijeka</city>
        <state>Primorsko-goranska Zupanija</state>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Split /ID# 152530</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava /ID# 142900</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Kuna-Peric /ID# 142901</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Bonifarm /ID# 142899</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum, s.r.o /ID# 145961</name>
      <address>
        <city>Hlučín</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTCenter MaVe, s.r.o. /ID# 142905</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucky Kraj</state>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav Praha /ID# 142904</name>
      <address>
        <city>Prague 2</city>
        <state>Praha 2</state>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuselská poliklinika, Revmatologie /ID# 144862</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologická ambulance /ID# 145963</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice /ID# 145962</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REVMACLINIC s.r.o. /ID# 142906</name>
      <address>
        <city>Brno</city>
        <zip>611 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie Bruntal, s.r.o /ID# 142903</name>
      <address>
        <city>Bruntál</city>
        <zip>79201</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka a interni ambul /ID# 142907</name>
      <address>
        <city>Kladno</city>
        <zip>272 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirov /ID# 142908</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthromed, s.r.o. /ID# 144706</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital /ID# 158838</name>
      <address>
        <city>Aarhus N</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionhospital Silkeborg /ID# 142914</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Clinical and Basic Research /ID# 142922</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediTrials /ID# 151870</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paernu Hospital /ID# 142921</name>
      <address>
        <city>Pärnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital /ID# 142923</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Estonian Medical Centre /ID# 145454</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Purpan /ID# 144707</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez /ID# 151312</name>
      <address>
        <city>Lille CEDEX</city>
        <state>Hauts-de-France</state>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi /ID# 142925</name>
      <address>
        <city>Montpellier CEDEX 5</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux-Hopital Pellegrin /ID# 145618</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Cote de Nacre /ID# 145616</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied /ID# 145619</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Conception /ID# 142926</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere /ID# 145605</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hospital Sud /ID# 151957</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg Hautepierre Hos /ID# 144708</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet /ID# 145620</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln /ID# 145964</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Walter, Rendsburg /ID# 142932</name>
      <address>
        <city>Rendsburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Versorgungszentrum AGILOME /ID# 154975</name>
      <address>
        <city>Chemnitz</city>
        <zip>9126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumaforschungszentrum II /ID# 142930</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München /ID# 142931</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Laiko /ID# 142934</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital Attikon /ID# 142933</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Ippokratio /ID# 142935</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital /ID# 142938</name>
      <address>
        <city>Hong Kong</city>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital /ID# 142939</name>
      <address>
        <city>Tuen Mun</city>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 142951</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft. /ID# 142953</name>
      <address>
        <city>Budapest III</city>
        <state>Pest</state>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatókórház /ID# 145621</name>
      <address>
        <city>Szombathely</city>
        <state>Vas</state>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center Orvosi es /ID# 145950</name>
      <address>
        <city>Veszprém</city>
        <state>Veszprem</state>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz /ID# 142952</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo /ID# 142950</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft. /ID# 153061</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 142948</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hevizgyogyfurdo es Szent Andra /ID# 142949</name>
      <address>
        <city>Heviz</city>
        <zip>8380</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiskunhalasi Semmelweis Korhaz /ID# 151944</name>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz /ID# 142954</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hosp /ID# 142957</name>
      <address>
        <city>Dublin</city>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Ctr /ID# 144709</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 152050</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center /ID# 151958</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lady Davis Carmel MC /ID# 142960</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 145965</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas /ID# 147528</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Citta della Salute Scienza /ID# 150070</name>
      <address>
        <city>Turin</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Luigi Sacc /ID# 142966</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.I. di Verona Policlinico /ID# 142963</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Nat Scientific Med Res Ctr /ID# 142971</name>
      <address>
        <city>Astana</city>
        <zip>010009</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karaganda State Medical Univ /ID# 153433</name>
      <address>
        <city>Karaganda</city>
        <zip>100008</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semey State Medical University /ID# 152659</name>
      <address>
        <city>Semey</city>
        <zip>071403</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital /ID# 147168</name>
      <address>
        <city>Shymkent</city>
        <zip>160000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ Hosp /ID# 162073</name>
      <address>
        <city>Daegu</city>
        <state>Daegu Gwang Yeogsi</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital /ID# 142977</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon Gwang Yeogsi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital /ID# 150886</name>
      <address>
        <city>Jung-gu</city>
        <state>Incheon Gwang Yeogsi</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital /ID# 142975</name>
      <address>
        <city>Gwangju</city>
        <state>Jeonranamdo</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospi /ID# 142979</name>
      <address>
        <city>Seongdong-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cath Univ Seoul St Mary's Hosp /ID# 142976</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Med /ID# 142973</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital /ID# 142978</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 142974</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD M+M Centers /ID# 142984</name>
      <address>
        <city>Adazi</city>
        <zip>2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital /ID# 142982</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.Saulites-Kandevicas PP /ID# 142985</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic ORTO /ID# 142983</name>
      <address>
        <city>Riga</city>
        <zip>1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical Univ Hosp /ID# 142981</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Lithuanian Univ Health Sc /ID# 142986</name>
      <address>
        <city>Kovno</city>
        <state>Kaunas</state>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital /ID# 142987</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Perempuan Zainab II /ID# 157862</name>
      <address>
        <city>Kota Bharu</city>
        <state>Kelantan</state>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang /ID# 156756</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak /ID# 142990</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Putrajaya /ID# 142989</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tuanku Ja afar /ID# 142988</name>
      <address>
        <city>Seremban</city>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinstile, S.A. de C.V. /ID# 144866</name>
      <address>
        <city>Cuauhtemoc</city>
        <state>Ciudad De Mexico</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Dr. Jose E. Gonz /ID# 142992</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invest y Biomed de Chihuahua /ID# 142996</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RM Pharma Specialists, S.A de C.V /ID# 142994</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jesús Nazareno /ID# 142993</name>
      <address>
        <city>Mexico City</city>
        <zip>06090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Peninsular de Investiga /ID# 148159</name>
      <address>
        <city>Mérida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital /ID# 143002</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Rheumatology Ltd /ID# 143001</name>
      <address>
        <city>Nelson</city>
        <zip>7010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timaru Medical Specialists Ltd /ID# 143000</name>
      <address>
        <city>Timaru</city>
        <zip>7910</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 145622</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz /ID# 143004</name>
      <address>
        <city>Toruń</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMED Sp.z o.o. Filia nr 1 /ID# 148189</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Kliniczne /ID# 152782</name>
      <address>
        <city>Cracow</city>
        <state>Malopolskie</state>
        <zip>30-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow /ID# 143005</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk Sc /Id# 143003</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 151960</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED Warszawa Targowek /ID# 157621</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteo-Medic spolka cywilna /ID# 143006</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163293</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163294</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163295</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silmedic Sp z o.o /ID# 152914</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i wspolnicy SJ /ID# 163300</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solumed Sp. zoo Cent Medyczne /ID# 152783</name>
      <address>
        <city>Poznan</city>
        <zip>60-425</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus /ID# 143007</name>
      <address>
        <city>Warsaw</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues De Reumatologia /ID# 148316</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar De Vila Nova /ID# 143010</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <state>Porto</state>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCA Braga - Hospital de Braga /ID# 148317</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Descobertas /ID# 160539</name>
      <address>
        <city>Lisbon</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Sao Joao, EPE /ID# 152871</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidade Local De Saude Do Alto Minho /ID# 143009</name>
      <address>
        <city>Viana Do Castelo</city>
        <zip>4901-858</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine /ID# 151961</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group /ID# 143011</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Dr. I. Cantacuzino /ID# 143012</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Dr. I. Cantacuzino /ID# 143017</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Sf. Maria /ID# 144868</name>
      <address>
        <city>Bucuresti</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Sf. Maria /ID# 144869</name>
      <address>
        <city>Bucuresti</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Sf. Maria /ID# 145966</name>
      <address>
        <city>Bucuresti</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Recuperare /ID# 144867</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ecomed SRL /ID# 144870</name>
      <address>
        <city>Oradea</city>
        <zip>410028</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Outpatient clinic#4,LLC /ID# 148319</name>
      <address>
        <city>Korolev</city>
        <state>Moskva</state>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 143138</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Clinical Center of FMBA /ID# 145627</name>
      <address>
        <city>Perm</city>
        <state>Permskiy Kray</state>
        <zip>614109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Novaya Klinika /ID# 143019</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol Skiy Kray</state>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University /ID# 144871</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tver Regional Clinical Hosp. /ID# 143026</name>
      <address>
        <city>Tver</city>
        <state>Tverskaya Oblast</state>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Сity Clinical Hospital #4 /ID# 143023</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medi /ID# 143028</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital Botkina /ID# 145628</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Univ Med and Dent /ID# 145623</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #5 /ID# 148318</name>
      <address>
        <city>Nizhnij Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg State Medical Academy /ID# 143018</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical Universit /ID# 143031</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II Dzhan Research Center /ID# 143027</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NW State Med Univ NA Mechnikov /ID# 143022</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican clinical hospital n /ID# 145626</name>
      <address>
        <city>UFA</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Clin Hosp /ID# 143030</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Rheumatology /ID# 143032</name>
      <address>
        <city>Belgrade</city>
        <state>Beograd</state>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Rheumatology /ID# 143035</name>
      <address>
        <city>Belgrade</city>
        <state>Beograd</state>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Rheumatology /ID# 143036</name>
      <address>
        <city>Belgrade</city>
        <state>Beograd</state>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Rheumatology /ID# 143037</name>
      <address>
        <city>Belgrade</city>
        <state>Beograd</state>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Special Hospital for Rheuma /ID# 143034</name>
      <address>
        <city>Novi Sad</city>
        <state>Vojvodina</state>
        <zip>21101</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina /ID# 143033</name>
      <address>
        <city>Novi Sad</city>
        <state>Vojvodina</state>
        <zip>21137</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDMAN s.r.o. /ID# 143045</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologická ambulancia Reum.hapi s.r.o. /ID# 147169</name>
      <address>
        <city>Nové Mesto Nad Váhom</city>
        <zip>915 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMACENTRUM s.r.o. /ID# 143041</name>
      <address>
        <city>Partizanske</city>
        <zip>958 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slovak research center Team Member, Thermium s.r.o. /ID# 147614</name>
      <address>
        <city>Pieštany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumex, s.r.o. /ID# 143043</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97 101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologicka ambulancia /ID# 144873</name>
      <address>
        <city>Sabinov</city>
        <zip>083 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TIMMED spol. s r.o. /ID# 144872</name>
      <address>
        <city>Stará Lubovna</city>
        <zip>06401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologicka ambulancia, LER /ID# 143044</name>
      <address>
        <city>Topolcany</city>
        <zip>955 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALBAMED s.r.o. /ID# 143042</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenacres Hospital /ID# 144710</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research Site /ID# 148320</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pretoria /ID# 148353</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jakaranda Hosp, Emmed Research /ID# 143046</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jakaranda Hosp, Emmed Research /ID# 145968</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Augustine's Hospital /ID# 143047</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Helderberg Clinical Tr /ID# 148322</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinical Research Tr /ID# 144874</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiervlei Trial Centre /ID# 153085</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winelands Medical Research Ctr /ID# 143048</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Un. Marques de Valdecilla /ID# 143050</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comple Hosp Univ de A Coruna /ID# 143051</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina S /ID# 153566</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Gaias /ID# 143052</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hosp Santiago /ID# 153727</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hosp /ID# 143058</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univ Hosp /ID# 143056</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University /ID# 143059</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital /ID# 143055</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital /ID# 143061</name>
      <address>
        <city>New Taipei City</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University /ID# 143060</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hosp /ID# 157940</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Ho /ID# 143057</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpa /ID# 156088</name>
      <address>
        <city>Cerrahpasa</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Fizik Tedavi Rehabilitasyon Egitim ve Arastırma Hastanesi /ID# 143063</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izmir Katip Celebi Ataturk Training &amp; Research Hospital /ID# 143062</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Revmocentr /ID# 143067</name>
      <address>
        <city>Kiev</city>
        <state>Kyiv</state>
        <zip>04070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospita /ID# 154450</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 143071</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnytska Oblast</state>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital /ID# 152025</name>
      <address>
        <city>Ivano-frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSC-Strazhesko Ist Cardiology /ID# 152030</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Municipal City Clinical /ID# 143068</name>
      <address>
        <city>Lviv</city>
        <zip>79007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa National Medical Univ /ID# 143072</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhia Regional Clinical /ID# 143069</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital /ID# 143074</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital /ID# 143077</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warrington + Halton Hosp NHS /ID# 143075</name>
      <address>
        <city>Warrington</city>
        <zip>WA5 1LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Kazakhstan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Netherlands</country>
  </removed_countries>
  <reference>
    <citation>Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28.</citation>
    <PMID>31287230</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <results_first_submitted>September 13, 2019</results_first_submitted>
  <results_first_submitted_qc>September 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2019</results_first_posted>
  <disposition_first_submitted>October 1, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 3, 2018</disposition_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Musculoskeletal disease</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint disease</keyword>
  <keyword>Anti-inflammatory agents</keyword>
  <keyword>Antirheumatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02629159/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02629159/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with moderately to severely active rheumatoid arthritis (RA) on a stable dose of methotrexate with an inadequate response were randomized at 286 study sites in 41 countries.
This study is currently ongoing; results are reported as of the data cut-off date of 02 February 2018, when all participants were to have completed Week 26.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 2:1:2 ratio to receive placebo, adalimumab, or upadacitinib. Randomization was stratified by prior exposure to biologic disease-modifying anti-rheumatic drug(s) (bDMARD) (yes/no) and geographic region.
Rescue therapy was offered to participants who met protocol-specified criteria at Weeks 14, 18, 22, or 26.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants randomized to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were switched to 15 mg upadacitinib QD.</description>
        </group>
        <group group_id="P2">
          <title>Adalimumab</title>
          <description>Participants randomized to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were switched to 15 mg upadacitinib orally QD.</description>
        </group>
        <group group_id="P3">
          <title>Upadacitinib</title>
          <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were switched to 40 mg adalimumab eow.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="651"/>
                <participants group_id="P2" count="327"/>
                <participants group_id="P3" count="651"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Assigned Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="651"/>
                <participants group_id="P2" count="327"/>
                <participants group_id="P3" count="650">One participant received a placebo injection but no oral study drug before discontinuing the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 14 on Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="620"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="620"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rescued at Week 14</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rescued at Week 18</title>
              <participants_list>
                <participants group_id="P1" count="48">One participant rescued at week 18 did not receive any dose of upadacitinib</participants>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rescued at Week 22</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="595"/>
                <participants group_id="P2" count="288"/>
                <participants group_id="P3" count="600"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set consisted of all randomized participants who received at least 1 dose of study drug (placebo, adalimumab, or upadacitinib).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
        </group>
        <group group_id="B2">
          <title>Adalimumab</title>
          <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
        </group>
        <group group_id="B3">
          <title>Upadacitinib</title>
          <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="651"/>
            <count group_id="B2" value="327"/>
            <count group_id="B3" value="651"/>
            <count group_id="B4" value="1629"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="12.24"/>
                    <measurement group_id="B2" value="53.7" spread="11.70"/>
                    <measurement group_id="B3" value="54.2" spread="12.08"/>
                    <measurement group_id="B4" value="53.9" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 40 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40 to 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="439"/>
                    <measurement group_id="B4" value="1108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="512"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="521"/>
                    <measurement group_id="B4" value="1292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="215"/>
                    <measurement group_id="B4" value="527"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="445"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="436"/>
                    <measurement group_id="B4" value="1102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="561"/>
                    <measurement group_id="B2" value="292"/>
                    <measurement group_id="B3" value="576"/>
                    <measurement group_id="B4" value="1429"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South/Central America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="432"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Western Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="262"/>
                    <measurement group_id="B4" value="656"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="8.00"/>
                    <measurement group_id="B2" value="8.3" spread="8.41"/>
                    <measurement group_id="B3" value="8.1" spread="7.73"/>
                    <measurement group_id="B4" value="8.2" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>A total of 68 joints were assessed for the presence or absence of tenderness.</description>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="14.30"/>
                    <measurement group_id="B2" value="26.4" spread="15.16"/>
                    <measurement group_id="B3" value="26.4" spread="15.15"/>
                    <measurement group_id="B4" value="26.2" spread="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>A total of 66 joints were assessed for the presence or absence of swelling.</description>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.2" spread="8.97"/>
                    <measurement group_id="B2" value="16.3" spread="9.19"/>
                    <measurement group_id="B3" value="16.6" spread="10.31"/>
                    <measurement group_id="B4" value="16.4" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Assessment of Pain</title>
          <description>Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100 mm. A score of 0 mm indicates &quot;no pain&quot; and a score of 100 mm indicates &quot;worst possible pain.&quot;</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="649"/>
                    <count group_id="B2" value="325"/>
                    <count group_id="B3" value="647"/>
                    <count group_id="B4" value="1621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" spread="20.67"/>
                    <measurement group_id="B2" value="66.2" spread="20.51"/>
                    <measurement group_id="B3" value="65.7" spread="21.02"/>
                    <measurement group_id="B4" value="65.5" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Global Assessment of Disease Activity</title>
          <description>The participant was asked to rate their current RA disease activity over the past 24 hours on a 100 mm VAS, where 0 mm indicates very low disease activity and 100 mm indicates very high disease activity.</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="649"/>
                    <count group_id="B2" value="324"/>
                    <count group_id="B3" value="647"/>
                    <count group_id="B4" value="1620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="21.49"/>
                    <measurement group_id="B2" value="65.8" spread="21.08"/>
                    <measurement group_id="B3" value="64.3" spread="21.83"/>
                    <measurement group_id="B4" value="64.4" spread="21.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Global Assessment of Disease Activity</title>
          <description>The physician rated the participant's current global RA disease activity (independently from the participant's assessment) on a VAS scale from 0 to 100 mm, where 0 mm indicates very low disease activity and 100 mm indicates very high disease activity.</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="620"/>
                    <count group_id="B2" value="305"/>
                    <count group_id="B3" value="616"/>
                    <count group_id="B4" value="1541"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.0" spread="18.17"/>
                    <measurement group_id="B2" value="65.1" spread="17.60"/>
                    <measurement group_id="B3" value="65.6" spread="17.06"/>
                    <measurement group_id="B4" value="65.7" spread="17.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="649"/>
                    <count group_id="B2" value="325"/>
                    <count group_id="B3" value="646"/>
                    <count group_id="B4" value="1620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.61"/>
                    <measurement group_id="B2" value="1.6" spread="0.59"/>
                    <measurement group_id="B3" value="1.6" spread="0.64"/>
                    <measurement group_id="B4" value="1.6" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="651"/>
                    <count group_id="B2" value="327"/>
                    <count group_id="B3" value="651"/>
                    <count group_id="B4" value="1629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" spread="21.52"/>
                    <measurement group_id="B2" value="19.8" spread="21.51"/>
                    <measurement group_id="B3" value="17.9" spread="22.49"/>
                    <measurement group_id="B4" value="18.3" spread="21.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score 28 Based on CRP (DAS28[CRP])</title>
          <description>The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score &gt; 5.1 indicates high disease activity, a DAS28 score ≤ 3.2 indicates low disease activity, and a DAS28 score &lt; 2.6 indicates clinical remission.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="649"/>
                    <count group_id="B2" value="324"/>
                    <count group_id="B3" value="647"/>
                    <count group_id="B4" value="1620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="0.94"/>
                    <measurement group_id="B2" value="5.9" spread="0.96"/>
                    <measurement group_id="B3" value="5.8" spread="0.97"/>
                    <measurement group_id="B4" value="5.8" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="32.7" upper_limit="40.1"/>
                    <measurement group_id="O2" value="63.0" lower_limit="57.8" upper_limit="68.2"/>
                    <measurement group_id="O3" value="70.5" lower_limit="67.0" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was the primary analysis for US/FDA regulatory purposes, and a ranked key secondary endpoint for EU/EMA regulatory purposes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>34.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.0</ci_lower_limit>
            <ci_upper_limit>39.2</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12</title>
        <description>The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission, based on a Disease Activity Score 28 (DAS28)-CRP score of &lt; 2.6 at Week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than 2.6 indicates clinical remission.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12</title>
          <description>The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission, based on a Disease Activity Score 28 (DAS28)-CRP score of &lt; 2.6 at Week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than 2.6 indicates clinical remission.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="4.3" upper_limit="8.0"/>
                    <measurement group_id="O2" value="18.0" lower_limit="13.9" upper_limit="22.2"/>
                    <measurement group_id="O3" value="28.7" lower_limit="25.2" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was the primary analysis for EU/EMA regulatory purposes, and a ranked key secondary endpoint for US/FDA regulatory purposes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>22.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>26.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.3</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (CRP) at Week 12</title>
        <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data at Baseline; multiple imputation was used for missing post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (CRP) at Week 12</title>
          <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.</description>
          <population>Full analysis set participants with available data at Baseline; multiple imputation was used for missing post-baseline data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="643"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" lower_limit="-1.276" upper_limit="-1.017"/>
                    <measurement group_id="O2" value="-2.01" lower_limit="-2.175" upper_limit="-1.848"/>
                    <measurement group_id="O3" value="-2.48" lower_limit="-2.608" upper_limit="-2.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) model with treatment, prior biological DMARD use, and Baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.469</ci_lower_limit>
            <ci_upper_limit>-1.194</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior biological DMARD use and Baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.638</ci_lower_limit>
            <ci_upper_limit>-0.295</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26</title>
        <description>The mTSS measures the level of joint damage from radiographs of the hands and feet, assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score.
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
JSN was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).
The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst). A negative change from Baseline in mTSS indicates improvement in joint damage whereas a change from Baseline greater than 0 indicates progression.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 26 or who were rescued prior to Week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26</title>
          <description>The mTSS measures the level of joint damage from radiographs of the hands and feet, assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score.
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
JSN was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).
The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst). A negative change from Baseline in mTSS indicates improvement in joint damage whereas a change from Baseline greater than 0 indicates progression.</description>
          <population>Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 26 or who were rescued prior to Week 26.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.64" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.25" upper_limit="0.46"/>
                    <measurement group_id="O3" value="0.24" lower_limit="-0.04" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior biological DMARD use and Baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.448</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior biological DMARD use and Baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
          <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="648"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="644"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" lower_limit="-0.339" upper_limit="-0.227"/>
                    <measurement group_id="O2" value="-0.49" lower_limit="-0.556" upper_limit="-0.415"/>
                    <measurement group_id="O3" value="-0.60" lower_limit="-0.653" upper_limit="-0.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior biological DMARD use and Baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.372</ci_lower_limit>
            <ci_upper_limit>-0.253</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA only.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior biological DMARD use and Baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.184</ci_lower_limit>
            <ci_upper_limit>-0.036</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="12.2" upper_limit="17.6"/>
                    <measurement group_id="O2" value="29.1" lower_limit="24.1" upper_limit="34.0"/>
                    <measurement group_id="O3" value="45.2" lower_limit="41.3" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority test of upadacitinib versus adalimumab was evaluated using the lower bound of the 95% confidence interval (CI) of the treatment difference against a non-inferiority margin of 10%. This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA only.</non_inferiority_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>16.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.9</ci_lower_limit>
            <ci_upper_limit>22.3</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA only.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>30.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.6</ci_lower_limit>
            <ci_upper_limit>35.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</title>
        <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</title>
          <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="616"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="616"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" lower_limit="2.79" upper_limit="4.33"/>
                    <measurement group_id="O2" value="6.27" lower_limit="5.31" upper_limit="7.23"/>
                    <measurement group_id="O3" value="7.89" lower_limit="7.11" upper_limit="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.52</ci_lower_limit>
            <ci_upper_limit>5.15</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</title>
        <description>The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</title>
          <description>The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="11.2" upper_limit="16.5"/>
                    <measurement group_id="O2" value="28.7" lower_limit="23.8" upper_limit="33.7"/>
                    <measurement group_id="O3" value="45.0" lower_limit="41.2" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>31.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.5</ci_lower_limit>
            <ci_upper_limit>35.8</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority test of upadacitinib versus adalimumab was evaluated using the lower bound of the 95% confidence interval (CI) of the treatment difference against a non-inferiority margin of 10%. This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for EU/EMA only.</non_inferiority_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>16.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.0</ci_lower_limit>
            <ci_upper_limit>22.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12</title>
        <description>Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom CDAI data were missing at Week 12 were considered non-responders</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12</title>
          <description>Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom CDAI data were missing at Week 12 were considered non-responders</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="13.4" upper_limit="19.1"/>
                    <measurement group_id="O2" value="30.0" lower_limit="25.0" upper_limit="34.9"/>
                    <measurement group_id="O3" value="40.4" lower_limit="36.6" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>24.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.4</ci_lower_limit>
            <ci_upper_limit>28.8</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>16.7</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duration of Morning Stiffness at Week 12</title>
        <description>Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duration of Morning Stiffness at Week 12</title>
          <description>Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="619"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.59" lower_limit="-58.84" upper_limit="-38.34"/>
                    <measurement group_id="O2" value="-82.71" lower_limit="-95.80" upper_limit="-69.62"/>
                    <measurement group_id="O3" value="-92.63" lower_limit="-103.03" upper_limit="-82.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-44.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.39</ci_lower_limit>
            <ci_upper_limit>-32.69</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.89</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</title>
        <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</title>
          <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="3.85" upper_limit="5.77"/>
                    <measurement group_id="O2" value="7.44" lower_limit="6.25" upper_limit="8.64"/>
                    <measurement group_id="O3" value="8.95" lower_limit="7.98" upper_limit="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA and EU/EMA.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.13</ci_lower_limit>
            <ci_upper_limit>5.16</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 12</title>
        <description>Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100. A score of 0 indicates &quot;no pain&quot; and a score of 100 indicates &quot;worst possible pain.&quot; A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 12</title>
          <description>Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100. A score of 0 indicates &quot;no pain&quot; and a score of 100 indicates &quot;worst possible pain.&quot; A negative change from Baseline indicates improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="616"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.46" lower_limit="-17.63" upper_limit="-13.29"/>
                    <measurement group_id="O2" value="-25.31" lower_limit="-28.16" upper_limit="-22.47"/>
                    <measurement group_id="O3" value="-31.76" lower_limit="-33.96" upper_limit="-29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for US/FDA only.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.63</ci_lower_limit>
            <ci_upper_limit>-3.27</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and Baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-16.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.89</ci_lower_limit>
            <ci_upper_limit>-13.71</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Radiographic Progression at Week 26</title>
        <description>No radiographic progression is defined as a change from Baseline in mTSS ≤ 0. The mTSS measures the level of joint damage from radiographs of the hands and feet, which were assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score and ranges from 0 (normal) to 448 (worst).
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
Joint space narrowing (JSN) was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 26 or who were rescued prior to Week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Radiographic Progression at Week 26</title>
          <description>No radiographic progression is defined as a change from Baseline in mTSS ≤ 0. The mTSS measures the level of joint damage from radiographs of the hands and feet, which were assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score and ranges from 0 (normal) to 448 (worst).
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
Joint space narrowing (JSN) was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).</description>
          <population>Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 26 or who were rescued prior to Week 26.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="72.5" upper_limit="79.4"/>
                    <measurement group_id="O2" value="86.8" lower_limit="83.0" upper_limit="90.7"/>
                    <measurement group_id="O3" value="83.5" lower_limit="80.5" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>In order to preserve Type I error, a step-down approach was used to test the primary and ranked key secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was a ranked key secondary endpoint in the pre-specified multiplicity testing sequence for EU/EMA only.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.0</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.187</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib</title>
            <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.3" upper_limit="6.6"/>
                    <measurement group_id="O2" value="13.5" lower_limit="9.8" upper_limit="17.2"/>
                    <measurement group_id="O3" value="24.9" lower_limit="21.6" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>20.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.3</ci_lower_limit>
            <ci_upper_limit>23.7</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This comparison was not part of the pre-specified multiplicity testing sequence.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological DMARD use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Adalimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to Week 26, or up to 30 days after last dose for those receiving placebo or upadacitinib who discontinued prior to Week 26, or up to 70 days after last dose for those receiving adalimumab who discontinued prior to Week 26.</time_frame>
      <desc>One participant randomized to upadacitinib received placebo to adalimumab but did not receive upadacitinib and is counted in the placebo group for analyses of safety.
One participant who switched from placebo to upadacitinib at Week 18 did not receive any upadacitinib and is therefore not counted in the placebo / upadacitinib treatment group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.
Includes events up to the time of rescue (at Weeks 14, 18, 22) or up to Week 26 for those who were not rescued.</description>
        </group>
        <group group_id="E2">
          <title>Adalimumab</title>
          <description>Participants received placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 15 mg upadacitinib orally QD.
Includes events up to the time of rescue (at Weeks 14, 18, 22) or up to Week 26 for those who were not rescued.</description>
        </group>
        <group group_id="E3">
          <title>Upadacitinib</title>
          <description>Participants randomized to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were switched to 40 mg adalimumab eow.
Includes events up to the time of rescue (at Weeks 14, 18, 22) or up to Week 26 for those who were not rescued.</description>
        </group>
        <group group_id="E4">
          <title>Placebo / Upadacitinib</title>
          <description>Participants who originally received placebo were switched at Weeks 14, 18, or 22 to receive 15 mg upadacitinib orally QD.
Includes all events that occurred after the switch to rescue treatment up to Week 26.</description>
        </group>
        <group group_id="E5">
          <title>Adalimumab / Upadacitinib</title>
          <description>Participants who originally received adalimumab were switched at Weeks 14, 18, or 22 to receive 15 mg upadacitinib orally QD.
Includes all events that occurred after the switch to rescue treatment up to Week 26.</description>
        </group>
        <group group_id="E6">
          <title>Upadacitinib / Adalimumab</title>
          <description>Participants who originally received 15 mg upadacitinib QD were switched at Weeks 14, 18, or 22 to receive 40 mg adalimumab eow.
Includes all events that occurred after the switch to rescue treatment up to Week 26.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="327"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="650"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR DILATATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>GASTRIC POLYPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>HEPATITIS TOXIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>BRONCHITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>FALLOPIAN TUBE ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>INFECTED BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>INFECTIOUS COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>AIRWAY COMPLICATION OF ANAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>VERTEBRAL LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DEMYELINATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>NEUROTOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PARAPLEGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SPINAL CORD HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIAL HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST RUPTURED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="327"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="650"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="652"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E3" events="42" subjects_affected="36" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="652"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E3" events="43" subjects_affected="37" subjects_at_risk="650"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

